查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1610203

腫瘤精準醫學市場：按類型、癌症類型、最終用途分類 - 2025-2030 年全球預測

Oncology Precision Medicine Market by Type (Cell & Gene Therapy, Inhibitor drugs, Monoclonal Antibodies), Cancer Type (Breast Cancer, Cervical Cancer, Colorectal Cancer), End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

腫瘤精準醫療市場2023年估值為73.4億美元，預計2024年將達到76.7億美元，複合年成長率為9.10%，到2030年將達到135.1億美元。

腫瘤精準醫療是指利用基因組、生物標記和其他分子訊息，根據每個患者的癌症特徵制定治療方案，以最佳化治療效果。精準醫療的需求是改善治療結果、減少副作用並簡化醫療服務。其應用範圍涵蓋診斷、治療監測和治療創新，對癌症中心、醫院和研究機構產生重大影響。最終用途範圍正在迅速擴大，包括個人化癌症疫苗、標靶治療和下一代定序技術。影響市場的主要成長要素包括基因組學的技術進步、癌症盛行率的增加、政府的有利舉措以及製藥和生物技術公司之間不斷加強的夥伴關係。該領域最近的機會在於整合人工智慧和巨量資料分析以提高預測準確性，以及開發具有成本效益的下一代定序方法以擴大可及性。精準醫學的應用還有可能不僅限於常見癌症，還包括罕見癌症和尚未充分治療的癌症類型。

主要市場統計
基準年[2023] 73.4億美元
預計年份 [2024] 76.7億美元
預測年份 [2030] 135.1億美元
複合年成長率（%） 9.10%

然而，先進診斷的高成本、資料管理的複雜性、監管障礙以及需要熟練的專業人員解釋複雜的遺傳資訊等挑戰對 Masu 的市場成長構成了重大限制。該領域的創新可以集中於開發強大的生物資訊解決方案、增強對癌症生物學的理解以及建立適應性臨床試驗設計。此外，與科技公司的合作可以增強資料驅動的洞察力，以改善患者分層和個人化治療方法。市場仍然高度活躍，競爭刺激了新診斷和治療方法的進步。為了利用新興趨勢，相關人員應投資合作研究，專注於以患者為中心的方法，並積極與政策制定者合作，以建立有利的法律規範，以改善日常臨床實踐。和整合精準腫瘤學。

市場動態：揭示快速發展的腫瘤精準醫學市場的關鍵市場洞察

腫瘤精準醫療市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 世界人口癌症發生率上升
    • 政府推動精準醫療的舉措
    • 更多採用基因檢測來加強精準醫療
  • 市場限制因素
    • 腫瘤精準醫學治療的報銷限制
  • 市場機會
    • 持續研究和開發癌症治療的個人化醫療
    • 腫瘤組織和液態切片臨床下一代定序的進展
  • 市場挑戰
    • 圍繞精準腫瘤學的複雜法律規範

波特五力：駕馭腫瘤精準醫學市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解腫瘤精準醫療市場的外在影響

外部宏觀環境因素在塑造腫瘤精準醫療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解腫瘤精準醫療市場的競爭格局

對腫瘤精準醫學市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣腫瘤精準醫療市場供應商績效評估

FPNV 定位矩陣是評估腫瘤精準醫學市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃腫瘤精準醫療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對腫瘤精準醫學市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界人口癌症發生率上升
      • 政府推動精準醫療的舉措
      • 擴大基因檢測的引入，加強精準醫療
    • 抑制因素
      • 腫瘤精準醫學治療的報銷有限
    • 機會
      • 持續研究和開發癌症治療的個人化醫療
      • 腫瘤組織和液態生物檢體臨床次世代定序的進展
    • 任務
      • 圍繞精準腫瘤學的複雜法規結構
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章腫瘤精準醫學市場：依類型

  • 細胞/基因治療
  • 抑制劑
  • 單株抗體

第7章依癌症類型分類的腫瘤精準醫學市場

  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌

第8章腫瘤精準醫學市場：依最終用途分類

  • 醫院和診斷實驗室
  • 製藥和生物技術公司

第9章美洲腫瘤精準醫療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太腫瘤精準醫療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲腫瘤精準醫療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • BJ Madan & Co.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cepheid Inc.
  • Eli Lilly & Company
  • F. Hoffmann-La Roche Ltd
  • Genome Medical boasts
  • GSK PLC
  • IQVIA Inc.
  • Laboratory Corporation of America Holding
  • llumina, Inc.
  • Merck KGaA
  • Novartis AG
  • OneOme, LLC
  • Pfizer Inc.
  • Rain Oncology Inc.
  • Relay Therapeutics
  • Sanofi SA
  • Strata Oncology, Inc.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Variantyx, Inc.
  • Xilis, Inc.
Product Code: MRR-5C6F41F5B030

The Oncology Precision Medicine Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.67 billion in 2024, and is projected to grow at a CAGR of 9.10%, to USD 13.51 billion by 2030.

Oncology precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient's cancer, leveraging genomic, biomarker, and other molecular information to optimize therapeutic efficacy. The necessity of precision medicine arises from its ability to improve treatment outcomes, reduce adverse effects, and enhance the efficiency of healthcare delivery. Its applications span across diagnosis, treatment monitoring, and therapeutic innovation, significantly impacting cancer centers, hospitals, and research institutions. The end-use scope is rapidly expanding to include personalized cancer vaccines, targeted therapies, and next-generation sequencing technologies. Key growth factors influencing the market include technological advancements in genomics, increasing prevalence of cancer, favorable government initiatives, and rising partnerships between pharmaceutical firms and biotech companies. Recent opportunities in this field lie in integrating artificial intelligence and big data analytics to enhance predictive accuracy and developing cost-effective next-generation sequencing methods to widen accessibility. There's also potential in expanding precision medicine applications beyond common cancers into rare and underserved cancer types.

KEY MARKET STATISTICS
Base Year [2023] USD 7.34 billion
Estimated Year [2024] USD 7.67 billion
Forecast Year [2030] USD 13.51 billion
CAGR (%) 9.10%

However, challenges such as high costs of advanced diagnostics, complexity in data management, regulatory hurdles, and a need for skilled professionals to interpret complex genetic information pose significant limitations to market growth. Innovation in this sector could focus on developing robust bioinformatics solutions, enhancing the understanding of cancer biology, and creating adaptive clinical trial designs. Furthermore, engaging in collaborations with technology firms could enhance data-driven insights, improving patient stratification and personalized treatment regimens. The market remains highly dynamic, with competition spurring advancements in novel diagnostics and therapeutic methodologies. To capitalize on emerging trends, stakeholders should invest in collaborative research, focus on patient-centric approaches, and actively engage with policymakers to facilitate favorable regulatory frameworks, thus driving broader adoption and integration of precision oncology in routine clinical practice.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Precision Medicine Market

The Oncology Precision Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of cancer among the global population
    • Government initiatives to promote precision medicine
    • Increasing adoption of genetic testing to enhance precision medicine
  • Market Restraints
    • Limited reimbursement available for oncology precision medicine treatment
  • Market Opportunities
    • Ongoing R&D to develop personalized medicine to treat cancer
    • Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
  • Market Challenges
    • Complex regulatory framework surrounding precision oncology

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Precision Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Precision Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Precision Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Precision Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Precision Medicine Market

A detailed market share analysis in the Oncology Precision Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Precision Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Precision Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Precision Medicine Market

A strategic analysis of the Oncology Precision Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, B. J. Madan & Co., Bayer AG, Bristol-Myers Squibb Company, Cepheid Inc., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, Genome Medical boasts, GSK PLC, IQVIA Inc., Laboratory Corporation of America Holding, llumina, Inc., Merck KGaA, Novartis AG, OneOme, LLC, Pfizer Inc., Rain Oncology Inc., Relay Therapeutics, Sanofi S.A., Strata Oncology, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Variantyx, Inc., and Xilis, Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Cell & Gene Therapy, Inhibitor drugs, and Monoclonal Antibodies.
  • Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End-use, market is studied across Hospitals & Diagnostic Laboratories and Pharmaceutical & Biotechnology Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of cancer among the global population
      • 5.1.1.2. Government initiatives to promote precision medicine
      • 5.1.1.3. Increasing adoption of genetic testing to enhance precision medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement available for oncology precision medicine treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to develop personalized medicine to treat cancer
      • 5.1.3.2. Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory framework surrounding precision oncology
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncology Precision Medicine Market, by Type

  • 6.1. Introduction
  • 6.2. Cell & Gene Therapy
  • 6.3. Inhibitor drugs
  • 6.4. Monoclonal Antibodies

7. Oncology Precision Medicine Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cervical Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Prostate Cancer

8. Oncology Precision Medicine Market, by End-use

  • 8.1. Introduction
  • 8.2. Hospitals & Diagnostic Laboratories
  • 8.3. Pharmaceutical & Biotechnology Companies

9. Americas Oncology Precision Medicine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncology Precision Medicine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Precision Medicine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. B. J. Madan & Co.
  • 4. Bayer AG
  • 5. Bristol-Myers Squibb Company
  • 6. Cepheid Inc.
  • 7. Eli Lilly & Company
  • 8. F. Hoffmann-La Roche Ltd
  • 9. Genome Medical boasts
  • 10. GSK PLC
  • 11. IQVIA Inc.
  • 12. Laboratory Corporation of America Holding
  • 13. llumina, Inc.
  • 14. Merck KGaA
  • 15. Novartis AG
  • 16. OneOme, LLC
  • 17. Pfizer Inc.
  • 18. Rain Oncology Inc.
  • 19. Relay Therapeutics
  • 20. Sanofi S.A.
  • 21. Strata Oncology, Inc.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Thermo Fisher Scientific, Inc.
  • 24. Variantyx, Inc.
  • 25. Xilis, Inc.

LIST OF FIGURES

  • FIGURE 1. ONCOLOGY PRECISION MEDICINE MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLOGY PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLOGY PRECISION MEDICINE MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023